A Multicenter, Randomized Trial to Compare 2 Link Nobori and 3 Link Xience Stents in Bifurcation Stenting

Trial Profile

A Multicenter, Randomized Trial to Compare 2 Link Nobori and 3 Link Xience Stents in Bifurcation Stenting

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Everolimus (Primary) ; Umirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BEGIN
  • Most Recent Events

    • 06 Apr 2017 The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years. Lastly Verified in April 2015
    • 01 Jun 2015 Status changed from recruiting to active, no longer recruiting as per University Hospital Medical Information Network - Japan.
    • 16 Apr 2013 New source identified and integrated (University Hospital Medical Information Network - Japan: UMIN000007764).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top